Berlin, Germany and Nevada, USA, September 05, 2017 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in seven upcoming scientific and investor conferences in the second half of 2017:
- Goldman Sachs Fourteenth Annual European Medtech and Healthcare Services Conference 2017
Date: September 6-7, 2017
Location: London, UK
Presentation: Ben J. Lipps, CEO of MagForce AG, Thursday, September 7, 2017; 16:00 BST - Berenberg & Goldman Sachs Sixth German Corporate Conference 2017
Date: September 18-20, 2017
Location: Munich, Germany
Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, September 19, 2017; 11:00 CET
- 17th European Congress of Neurosurgery (EANS 2017)
Date: October 1-5, 2017
Location: Venice, Italy
Booth: L, level: first floor
- International Brain Tumour Alliance (IBTA) Patient’s Advocate Conference
Date: October 19-22, 2017
Location: London, UK
- MEDICA 2017
Date: November 13-16, 2017
Location: Düsseldorf, Germany
Community booth: Berlin Partner für Wirtschaft und Technologie GmbH No. 15F42, hall 15
- 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO)
Date: November 16-19, 2017
Location: San Francisco, California, USA
Booth: Golden Gate foyer , level: B1
Presentation: EXPERIMENTAL THERAPEUTICS AND TUMOR MODELS,
‘Combined intracavitary thermotherapy with iron-oxide nanoparticles and radiotherapy as a promising treatment modality in recurrent GBM’ (SURG-32)
Presenter: Team of Prof. Dr. med. Walter Stummer, Director of the Clinic for Neurosurgery, University Hospital Münster
Speaker: PD Dr. Dr. med. Oliver Grauer, Head of Neuro-Oncology Team, University Hospital Münster
Date of presentation: Session 2C, Friday, November 17, 2017, 13:45 PDT - German Equity Forum 2017
Date: November 27-29, 2017
Location: Frankfurt, Germany
Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, September 28, 2017; 16:30 CET
Room: Oslo
About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group’s proprietary NanoTherm therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.
NanoTherm, NanoPlan, and NanoActivator are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.
